Press Releases

InspireMD Announces Renowned Interventional Cardiologist Gary S. Roubin, M.D., Ph.D., to Join Board of Directors

Tel Aviv, Israel — October 13, 2020 – InspireMD, Inc. (NYSE American: NSPR), the developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by carotid artery disease (CAD), today announced the addition of Gary Roubin, M.D., Ph.D., to InspireMD’s Board of Directors. Dr. Gary Roubin is an internationally renowned interventional… Read More

InspireMD, Inc. Appoints Patrick Jamnik as Vice President of Business Development and Strategic Initiatives and Reports Inducement Grants Under NYSE American Company Guide §711(a)

Tel Aviv, Israel – October 6, 2020 – InspireMD, Inc. (NYSE American: NSPR) (“Company”), the developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by carotid artery disease (CAD), today announced the appointment of Patrick Jamnik as vice president, business development and strategic initiatives.  In this newly created position, Mr…. Read More

InspireMD Announces Christina Brennan, M.D., MBA to Serve in Advisory Role for Pivotal Study of CGuard Carotid Stent System

Advancing the CARENET-III study of CGuard System for Stroke Prevention in the United States Tel Aviv, Israel — September 10, 2020 – InspireMD, Inc. (NYSE American: NSPR), the developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by carotid artery disease (CAD), today announced the addition of Dr. Christina Brennan… Read More

InspireMD Announces the European Society of Cardiology 2020 “Best Poster Award” for Updated Data from the PARADIGM-EXTEND Study

Tel Aviv, Israel — September 3, 2020 – InspireMD, Inc. (NYSE American: NSPR), the developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by carotid artery disease (CAD), today announces the award for Best ESC Congress Poster for the  presentation of updated data from the large, long-term PARADIGM-EXTEND study of… Read More

InspireMD to Present at the LD Micro 500 Virtual Conference on September 3, 2020

Tel Aviv, Israel — August 25, 2020 – InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by the treatment of carotid artery disease, today  announced that Marvin Slosman, President and Chief Executive Officer, will give a virtual corporate presentation at the LD Micro 500… Read More

InspireMD Regains Compliance with NYSE AMERICAN Listing Standards

Tel Aviv, Israel — August 10, 2020 – InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by the treatment of carotid artery disease, today announced that as of August 7, 2020, the Company has regained compliance with the NYSE American’s continued listing standards. As… Read More

InspireMD Announces Second Quarter 2020 Financial Results

 In the second quarter the Company was granted approval to market its CGuard™ MicroNet™ stent in Brazil and completed an $11.5 million capital raise; reported outstanding results in studies treating patients with the CGuard™ MicroNet™ stent  Management to host investor conference call today, August 5, 2020 at 8:30am ET   Tel Aviv, Israel— August 5,… Read More